Yves Bikorimana: What Every Lab and Clinician Should Know on Pseudothrombocytopenia
Yves Bikorimana, CEO at MedData-Rwanda and Lab Scientist at The University Teaching Hospital of Kigali-Chuk, shared a post on LinkedIn.
“Pseudothrombocytopenia (PTCP): What Every Lab and Clinician Should Know
Pseudothrombocytopenia is a laboratory artifact where platelet counts appear falsely low on automated analyzers, despite the patient having a normal platelet count in vivo. Importantly, it is not a true clinical thrombocytopenia and does not increase bleeding risk.
Why does it happen?
The most common cause is EDTA-dependent platelet clumping. In some individuals, EDTA (the anticoagulant used in routine CBC tubes) exposes platelet surface antigens, leading to antibody-mediated platelet aggregation. Automated analyzers then misinterpret these clumps as leukocytes or exclude them entirely, resulting in a falsely low platelet count.
Key Laboratory Features
- Low platelet count on automated CBC
- Platelet clumps visible on peripheral blood smear
- Normal platelet count when blood is collected in:
- Sodium citrate
- Heparin
- Magnesium sulfate (rarely used but effective)
Clinical Significance
- Patients are usually asymptomatic
- No bleeding manifestations
- Can be mistaken for serious conditions like:
- Immune thrombocytopenic purpura (ITP)
- Bone marrow disorders
- Drug-induced thrombocytopenia
Why recognition matters
Failure to identify PTCP can lead to:
- Unnecessary platelet transfusions
- Inappropriate treatments (e.g., steroids, IVIG)
- Delays in surgeries or invasive procedures
- Patient anxiety and misdiagnosis
Best Practice Approach
- Always review the peripheral smear when thrombocytopenia is detected
- Repeat platelet count using an alternative anticoagulant
- Correlate laboratory findings with clinical presentation
Take-home message
Pseudothrombocytopenia highlights the importance of laboratory-clinical correlation and the continued value of manual smear examination in modern diagnostics.”
Find the latest updates on Hemostasis Today.
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community
-
Sep 5, 2026, 19:06Katherine Blackwell: Blessed to Have the Opportunity to Speak at the Hemophilia of Indiana Annual Meeting
-
Sep 5, 2026, 19:04Christy V.: What You Need to Know about GI Bleeding and Hemophilia